Christopher Smith (R-NJ)

Stem Cell Therapeutic and Research Reauthorization Act of 2025

H.R. 5160 · House bill Health

A Republican bill with 11 Democratic cosponsors · See all 21 cosponsors

Last activity — Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.

Waiting for a floor vote in the other chamber

Passed one chamber and is on the other chamber's calendar.

The calendar is a queue, not a date. The majority leadership decides what comes to the floor and when; much of what is placed on it is never called, and a bill that is never called simply expires with the Congress.

Its path through Congress

  1. Introduced
  2. Passed House voice vote
  3. Awaiting Senate
  4. On Senate calendar

The House by voice vote (members called out yes or no together): no member's position on it was recorded.

What this bill would do

This Act, known as the Stem Cell Therapeutic and Research Reauthorization Act of 2025, serves to reauthorize the Stem Cell Therapeutic and Research Act of 2005. It updates the funding for the C.W. Bill Young Cell Transplantation Program by setting appropriations for fiscal years 2027 through 2031. The bill also modifies how the National Cord Blood Inventory is managed and defined. It changes the specific requirement for the number of cord blood units to a supply level determined by the Secretary. Additionally, it provides the Secretary with authority to transfer units to ensure continued availability and manage the inventory's size and composition.

Yes· 3 of 4

  • Scored +5

    Does this make health care easier to get in general?

    The bill enhances the management and availability of high-quality cord blood units through updated inventory protocols and increased funding.

  • Scored +4

    Does this put more money into medical research?

    The bill increases funding for the cell transplantation program and directs the Secretary to use current scientific and clinical information for inventory management.

  • Scored +4

    Would children be better off under this?

    Increased cord blood inventory management and funding can improve medical options available for children requiring cell transplants.

The opposite

No question was scored the opposite.